Involving A Nucleic Acid Encoding A Protein Related To The Nervous System, (e.g., Nerve Related Factors, Brain-derived Cytokines, Nerve Cell Biomarker, Etc.) Patents (Class 435/6.16)
-
Patent number: 10316317Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.Type: GrantFiled: March 6, 2018Date of Patent: June 11, 2019Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 10317329Abstract: Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.Type: GrantFiled: October 7, 2016Date of Patent: June 11, 2019Assignee: GENZYME CORPORATIONInventors: Victor R. Cairns, Christine DeMaria, Jason Vitko
-
Patent number: 10300451Abstract: The present disclosure provides a method for generating an affinity reagent library against a target protein which interacts with a ligand, which comprises the following steps; •i) determining one or more structural element(s) of the ligand which are involved in ligand: target protein interaction; •ii) producing a library of peptides which retain these structural element(s); and •iii) grafting each peptide from the library of peptides into a portion of the affinity reagent molecule such that it may interact with the target protein, in order to produce an affinity reagent library.Type: GrantFiled: June 19, 2014Date of Patent: May 28, 2019Assignees: Queen Mary University of London, University of KentInventors: Ahuva Nissim, John Marshall, Mark Howard
-
Patent number: 10302634Abstract: Devices, methods, and systems are provided for extracting particles from a ferrofluid and for rapid affinity measurements. Such systems may comprise a fluidic channel or chamber configured to include a ferrofluid having a plurality of target particles and background particles. The systems may include a capture region configured to capture at least a portion of the plurality of target particles. In addition, the systems include a first magnetic field generator and a second magnetic field generator. The first magnetic field generator may be arranged proximate to the fluidic channel, the first magnetic field generator being configured to generate a first magnetic field configured to direct the plurality of target particles towards the capture region. The second magnetic field generator can be arranged to be proximate to the capture region, and is further configured to generate an affinity thresholding magnetic field configured to remove background particles from the capture region.Type: GrantFiled: July 1, 2016Date of Patent: May 28, 2019Assignee: ANCERA, LLCInventor: Hur Koser
-
Patent number: 10302645Abstract: A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, PIN (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (BPH); a method to combine immunofluorescence and FISH (IF-FISH) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.Type: GrantFiled: February 27, 2017Date of Patent: May 28, 2019Assignee: Abbott Molecular Inc.Inventors: Ying Zhang, Larry Morrison, Ekaterina Pestova, Irina Sokolova
-
Patent number: 10294503Abstract: Provided herein are methods for processing biomass materials that are disposed in one or more structures or carriers, e.g., a bag, a shell, a net, a membrane, a mesh or any combination of these. Containing the material in this manner allows it to be readily added or removed at any point and in any sequence during processing.Type: GrantFiled: April 5, 2018Date of Patent: May 21, 2019Assignee: Xyleco, Inc.Inventors: Marshall Medoff, Thomas Craig Masterman, James Lynch
-
Patent number: 10294288Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 27, 2018Date of Patent: May 21, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10288624Abstract: The present invention relates to a method of predicting animal litter size using a fertility-related protein marker, and more particularly, to the discovery of a sperm marker that is expressed differently depending on animal fertility, a marker composition for predicting litter size, which comprises an antibody that binds specifically to the marker, and a method of predicting animal litter size using the marker composition. Moreover, the present invention relates to a method of predicting animal semen quality and litter size by chlortetracycline staining, and more particularly, to a method of predicting of animal litter size by measuring the motility, motion kinematics or capacitation status of sperm. When the animal sperm-derived protein marker according to the present invention is used, the litter size of individuals can be predicted by analyzing a protein that is expressed differently depending on litter size.Type: GrantFiled: May 13, 2015Date of Patent: May 14, 2019Assignee: CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Myung-Geol Pang, Woo-Sung Kwon
-
Patent number: 10280463Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.Type: GrantFiled: February 6, 2014Date of Patent: May 7, 2019Assignee: Wake Forest University Health SciencesInventors: Stephen Walker, Arthur Krigsman
-
Patent number: 10280462Abstract: The invention relates to PCR-based clonality studies for among others early diagnosis of lymphoproliferative disorders. Provided is a set of nucleic acid amplification primers comprising a forward primer, or a variant thereof, and a reverse primer, or a variant thereof, capable of amplifying a rearrangement selected from the group consisting of a VH-JH IGH rearrangement, a DH-JH IGH rearrangement, a VK-J? IGK rearrangement, a VK/intron-Kde IGK rearrangement, a V?-J? IGL rearrangement, a V?-J? TCRB rearrangement, a D?-J? TCRB rearrangement, a V?-J? TCRG rearrangement, a V?-J? TCRD rearrangement, a D?-D? TCRD rearrangement, a D?-J? TCRD rearrangement, a V?-D? TCRD rearrangement, or a translocation selected from t(11;14)(BCL1-IGH) and t(14;18)(BCL2-IGH). The primers can be used in PCR-based clonality studies for early diagnosis of lymphoproliferative disorders and detection of minimal residual disease (MRD). Also provided is a kit comprising at least one set of primers of the invention.Type: GrantFiled: June 23, 2014Date of Patent: May 7, 2019Inventors: Jacobus Johannes Maria Van Dongen, Anthonie Willem Langerak, Eduardus Maria Dominicus Schuuring, Jesus Fernando San Miguel, Ramon Garcia Sanz, Antonio Parreira, John Lewis Smith, Frances Louise Lavender, Gareth John Morgan, Paul Anthony Stuart Evans, Michael Kneba, Michael Hummel, Elizabeth Anne Macintyre, Christian Bastard, Frederic Bernard Louis Davi, Monika Brüggemann
-
Patent number: 10266892Abstract: The invention relate to systems and methods for sequencing polynucleotides, as well as detecting reactions and binding events involving other biological molecules. The systems and methods may employ chamber-free devices and nanosensors to detect or characterize such reactions in high-throughput. Because the system in many embodiments is reusable, the system can be subject to more sophisticated and improved engineering, as compared to single use devices.Type: GrantFiled: June 13, 2018Date of Patent: April 23, 2019Assignee: GENAPSYS, INC.Inventors: Hesaam Esfandyarpour, Kosar Baghbani Parizi, Mark F. Oldham, Eric S. Nordman, Richard T. Reel, Susanne Baumhueter, Cheryl Heiner, Frank Lee
-
Patent number: 10266874Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.Type: GrantFiled: June 3, 2014Date of Patent: April 23, 2019Assignee: The General Hospital CorporationInventors: Ralph Weissleder, Sarit S. Agasti, Vanessa M. Peterson, Adeeti Ullal
-
Patent number: 10266880Abstract: The present invention relates to the technical field of molecular biology, provides a method for measuring short RNA using amplified DNA fragment length polymorphism, and comprises the following steps: first using at least two synthesized miRNAs as the internal measurement standard, said synthesized miRNAs containing no natural homologous sequence in comparison with the short RNA to be measured, and mixing the synthesized miRNAs using different molecule numbers so as to form a dynamic miRNA standard molecular gradient; mixing the same quantity of the dynamic miRNA standard with the short RNA to be measured, and performing RNA reverse transcription, cDNA tailing, PCR synchronous amplification, and fluorescent quantitative analysis on the length polymorphism fragment of the PCR product DNA so as to measure the relative ratio of the fluorescence intensity of the DNA fragment produced by the amplification of the short RNA to be measured to the dynamic miRNA standard fluorescence intensity gradient.Type: GrantFiled: September 15, 2015Date of Patent: April 23, 2019Inventors: Kai Xu, Fang Tang, Yaoyi Zhang, Zihao Feng, Yu Yang, Xiujin Wu, Feifei Zhang
-
Patent number: 10260096Abstract: Disclosed herein is a system and method for increasing the fidelity of measured genetic data, for making allele calls, and for determining the state of aneuploidy, in one or a small set of cells, or from fragmentary DNA, where a limited quantity of genetic data is available. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed using expected similarities between the target genome and the genome of genetically related individuals. In accordance with one embodiment, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the more complete genetic data from a larger sample of diploid cells from one or both parents, with or without haploid genetic data from one or both parents. In another embodiment, the chromosome copy number can be determined from the measured genetic data, with or without genetic information from one or both parents.Type: GrantFiled: March 1, 2017Date of Patent: April 16, 2019Assignee: Natera, Inc.Inventors: Matthew Rabinowitz, Milena Banjevic, Zachary Demko, David Johnson, Dusan Kijacic, Dimitri Petrov, Joshua Sweetkind-Singer, Jing Xu
-
Patent number: 10253376Abstract: LAMP primer sets for detecting eight mastitis pathogens are disclosed. Methods and kits of using the primer sets to simultaneously detect at least two of the eight mastitis pathogens are also described.Type: GrantFiled: October 13, 2014Date of Patent: April 9, 2019Assignee: Wisconsin Alumni Research FoundationInventors: Doerte Doepfer, Kelly Anklam
-
Patent number: 10253374Abstract: Differentially expressed miRNA or small mRNA in the culture media of embryos were found to correlate to and affect embryo developmental fate. Accordingly the present invention provides a method for selecting a bovine embryo for implantation into a female bovine animal for further development based on the levels of specific miRNA or small mRNA. Also provided are methods of improving bovine embryo development fate by reducing in the culture medium the level of selected miRNAs.Type: GrantFiled: May 15, 2016Date of Patent: April 9, 2019Assignee: Wisconsin Alumni Research FoundationInventor: Hasan Khatib
-
Patent number: 10247738Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.Type: GrantFiled: April 25, 2018Date of Patent: April 2, 2019Assignee: DIGNITY HEALTHInventors: Jiong Shi, Peng Cheng Han
-
Patent number: 10238726Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 22, 2018Date of Patent: March 26, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10238725Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 22, 2018Date of Patent: March 26, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10221413Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Uncoupling Protein 2 (UCP2), in particular, by targeting natural antisense polynucleotides of Uncoupling Protein 2 (UCP2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of UCP2.Type: GrantFiled: May 28, 2015Date of Patent: March 5, 2019Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 10208348Abstract: Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The percentage of fetal DNA can be calculated from the same or different data used to determine the cutoff value, and can use a locus where the mother is homozygous and the fetus is heterozygous. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT).Type: GrantFiled: September 18, 2013Date of Patent: February 19, 2019Assignee: The Chinese University of Hong KongInventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Kwan Chee Chan, Benny Chung-Ying Zee, Ka Chun Chong
-
Patent number: 10207271Abstract: Complete nucleic acid library preparation devices are provided. Aspects of the devices include: a thermal chip module comprising multiple CLC reaction wells; one or more plate locations; a robotically controlled liquid handler configured to transfer liquid between the one or more plate locations and the thermal chip module; and a bulk reagent dispenser configured to access each CLC reaction well of the thermal chip module.Type: GrantFiled: August 3, 2015Date of Patent: February 19, 2019Assignee: GENCELL BIOSYSTEMS LTD.Inventors: Brian Barrett, Noel Sirr, Brian Chawke, Kieran Curran, John Daly
-
Computer implemented system and method for assessing a neuropsychiatric condition of a human subject
Patent number: 10204707Abstract: A method for assessing a neuropsychiatric condition (such as, but not limited to, a risk that a subject may attempt to commit suicide or repeat an attempt to commit suicide, a risk that terminally ill patient is not being care-for or treated according to the patient's true wishes, a risk that a subject may perform or repeat a criminal act and/or a harmful act, a risk of the subject having a psychiatric illness, and/or a risk of a subject feigning a psychiatric illness) may include a plurality of steps. A step may include receiving biomarker data associated from an analysis of the subject's biological sample and a step of receiving thought-marker data obtained pertaining to one or more of the subject's recorded thoughts, spoken words, transcribed speech, and writings. A step may include generating a biomarker score associated with the neuropsychiatric condition from the biomarker data.Type: GrantFiled: April 27, 2010Date of Patent: February 12, 2019Assignee: Children's Hospital Medical CenterInventors: John Pestian, Tracy A. Glauser, Bruce Aronow -
Patent number: 10202640Abstract: Methods and oligonucleotide reagents for analyzing individual T cells are disclosed. In particular, the present disclosure provides methods for analyzing individual T cells using high-throughput multiplex amplification and deep sequencing of nucleic acids encoding T cell receptors (TCRs) and various other T cell phenotypic markers. The present disclosure further provides methods of reconstituting TCRs from individual T cells for functional studies, ligand discovery, or screening therapeutics.Type: GrantFiled: April 30, 2015Date of Patent: February 12, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark M. Davis, Jacob Glanville, Arnold Han
-
Patent number: 10198553Abstract: The invention combines the fields of comparative genomic hybridization (CGH) analysis and SNP array analysis. It relates to methods for detecting and mapping genetic abnormalities associated with various diseases. In particular the invention provides a method for simultaneously performing array CGH and SNP array analysis on a genomic DNA sample comprising contacting a nucleic acid array which comprises a first probe set and a second probe set with a genomic DNA sample, comprising a test and reference sample, under hybridization conditions, comparing the amount of test sample and reference sample hybridized to the hybridization probes of the first probe set, comparing the amount of test sample and reference sample hybridized to the hybridization probes of the second probe set; and using the data obtained to determine the copy number of at least one locus; and at least one SNP in the genomic DNA sample.Type: GrantFiled: January 23, 2017Date of Patent: February 5, 2019Assignee: OXFORD GENE TECHNOLOGY (OPERATIONS) LTD.Inventors: Douglas Hurd, Edwin Southern
-
Patent number: 10196708Abstract: This disclosure provides engineered microbes modified such that the surface of the microbe contains one or more rare earth element (REE) binding ligands, as well as methods of use thereof.Type: GrantFiled: January 6, 2017Date of Patent: February 5, 2019Assignee: Lawrence Livermore National Security, LLCInventors: Yongqin Jiao, Dan Mcfarland Park, Mimi Cho Yung, David W. Reed
-
Patent number: 10196604Abstract: Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.Type: GrantFiled: June 19, 2015Date of Patent: February 5, 2019Assignees: The Board of Trustees of the Leland Stanford Junior University, Board of Regents of the University of Texas SystemInventors: David Alvin Tyvoll, Christopher S. Navara, James P. Collman, Christopher Jeffrey Barile
-
Patent number: 10184941Abstract: The invention relates to use of ACY-1 as a biomarker for ischaemia-reperfusion injury.Type: GrantFiled: March 13, 2014Date of Patent: January 22, 2019Assignee: University of LeedsInventors: Rosamonde Elizabeth Banks, Matthew Peter Welberry Smith, Peter John Selby, Andrew Lewington
-
Patent number: 10184002Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.Type: GrantFiled: March 1, 2016Date of Patent: January 22, 2019Assignee: AMGEN INC.Inventors: Marc A. Gavin, Ai Ching Lim
-
Patent number: 10176295Abstract: Contemplated systems and methods employ chimeric reference sequences that include a plurality of viral genome sequences to identify/quantify integration and co-amplification events. Most typically, the viral genome sequences are organized in the chimeric reference sequences as single chromosomes and the chimeric reference sequences are in BAM format.Type: GrantFiled: September 26, 2014Date of Patent: January 8, 2019Assignees: Five3 Genomics, LLC, Nant Holdings IP, LLCInventors: John Zachary Sanborn, Charles Joseph Vaske, Stephen Charles Benz, Shahrooz Rabizadeh, Nicole Hensley, Patrick Soon-Shiong
-
Patent number: 10175174Abstract: Methods comprising the use of photoactivated chemical bleaching for detecting multiple targets in a biological sample are provided. The methods include the steps of providing a biological sample including multiple targets, binding at least one probe to one or more target present in the sample, and detecting a signal from the probe. The method further includes the steps of contacting the sample comprising the bound probe with an electron transfer reagent, as well as an optional additive which prevents target modification during photoactivated chemical bleaching, and irradiating the sample, thereby initiating a photoreaction that substantially inactivates the probe by photoactivated chemical bleaching. The method further includes the steps of binding at least one probe to one or more target present in the sample, and detecting a signal from the probe. The process of binding, defecting and bleaching may be iteratively repeated.Type: GrantFiled: December 11, 2013Date of Patent: January 8, 2019Assignee: GE HEALTHCARE BIO-SCIENCES CORP.Inventors: Arunkumar Natarajan, Robert John Filkins, Anup Sood, Lakshmi Sireesha Kaanumalle, Kashan Ali Shaikh, Christina Lowes
-
Patent number: 10174365Abstract: The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analyzing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.Type: GrantFiled: January 16, 2012Date of Patent: January 8, 2019Assignees: STICHTING VU-VUMC, VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORGInventors: Thomas Wurdinger, Rolf Jonas Nilsson
-
Patent number: 10174364Abstract: The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analyzing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.Type: GrantFiled: July 15, 2011Date of Patent: January 8, 2019Assignee: STICHTING VU-VUmcInventors: Thomas Würdinger, Rolf Jonas Nilsson
-
Patent number: 10166304Abstract: The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.Type: GrantFiled: July 10, 2015Date of Patent: January 1, 2019Assignee: Regents of the University of MinnesotaInventors: Jayanth Panyam, Stephen Kalscheuer
-
Patent number: 10161006Abstract: The present invention relates to a method for screening a risk group of a hematologic disease and a method for analyzing the prognosis of a hematologic disease based on the measurement of the level of gelsolin mRNA in buffy coat of peripheral blood or a bone marrow aspirate. The use of the present invention enables the screening of a risk group of a hematologic disease and the analysis of prognosis of a patient with a hematologic disease in an easy and accurate manner.Type: GrantFiled: March 11, 2015Date of Patent: December 25, 2018Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Eun Jung Baek, Eun-Mi Lee
-
Patent number: 10155992Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.Type: GrantFiled: March 4, 2016Date of Patent: December 18, 2018Assignee: ADAPTIVE BIOTECHNOLOGIES CORP.Inventors: Malek Faham, Thomas Willis
-
Patent number: 10151698Abstract: The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, by compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsules; and identifying the compound which binds to or modulates the activity of the target. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development.Type: GrantFiled: December 27, 2017Date of Patent: December 11, 2018Assignee: United Kingdom Research and InnovationInventors: Andrew David Griffiths, Chris Abell, Florian Hollfelder, Enrico Mastrobattista
-
Patent number: 10149855Abstract: A method of reducing a subject's plasma triglyceride level, comprising administering to a subject in need thereof a gamma-secretase inhibitor in an amount effective to reduce the subject's plasma triglyceride level.Type: GrantFiled: February 4, 2015Date of Patent: December 11, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventor: Utpal Pajvani
-
Patent number: 10138475Abstract: The present invention concerns the use of methods and compositions for the isolation of small RNA molecules (100 nucleotides or fewer), such as microRNA and siRNA molecules. Such molecules are routinely lost in commonly used isolation procedures and therefore the present invention allows for a much higher level of enrichment or isolation of these small RNA molecules.Type: GrantFiled: October 19, 2015Date of Patent: November 27, 2018Assignee: APPLIED BIOSYSTEMS, LLCInventor: Richard Conrad
-
Patent number: 10140369Abstract: A computer implemented system for collating and presenting multi-format information in a user-desired format is envisaged. The system stores information related to clients along with additional their personal information in a transient repository. These stored items of information are usually in different formats, including text format, image format and video format, which are then converted by the system into a format desired by the user of the system or into a pre-defined format. An input module present in the system accepts form a user, a desired output information format type and a client identifier corresponding to the client whose information needs to be collated. Based on the client identifier, the system converts the stored client related information in the desired format and then collates and displays the converted information for further processing.Type: GrantFiled: June 24, 2015Date of Patent: November 27, 2018Assignee: VF Worldwide Holdings LimitedInventors: Falguni Jignesh Desai, Vishwas Mukund Pathak, Bharat Chamanlal Bhardwaj
-
Patent number: 10131948Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.Type: GrantFiled: July 17, 2014Date of Patent: November 20, 2018Assignee: UNIVERSITY OF MIAMIInventors: Joshua M. Hare, Bettina Heidecker
-
Patent number: 10125363Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.Type: GrantFiled: July 20, 2015Date of Patent: November 13, 2018Assignee: nLife Therapeutics, S.L.Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
-
Patent number: 10106851Abstract: A method of inhibiting light-induced degradation of nucleic acids includes irradiating a portion of the nucleic acids in the presence of a detection solution comprising a polyphenolic compound. A method of detecting a nucleic acid having a fluorescent tag includes irradiating at least a portion of the nucleic acid with light of a suitable wavelength to induce a fluorescence emission and detecting the fluorescence emission. Optionally, the polyphenolic compound is gallic acid, a lower alkyl ester thereof, or mixtures thereof. A kit includes one or more nucleotides, an enzyme capable of catalyzing incorporation of the nucleotides into a nucleic acid strand and a polyphenolic compound suitable for preparing a detection solution.Type: GrantFiled: December 8, 2017Date of Patent: October 23, 2018Assignee: Illumina, Inc.Inventors: Kay Klausing, Min-Jui Richard Shen, John Moore, Vincent Peter Smith, Kevin Hall
-
Patent number: 10106799Abstract: The present invention relates to nucleic acid constructs comprising selectable marker genes in a multicistronic transcription unit for use in the generation and selection of eukaryotic host cells for expression of a gene product of interest. For increased stringency of selection, the coding sequence of the selectable marker may be directed preceded by a relatively short functional open reading frame to reduce the efficiency of translation of the selectable marker, and/or the amino acid sequence of the selectable marker may comprise one or more mutations that reduce the level of resistance provide by the mutated marker as compared to its wild type counterpart. The invention further relates to methods for generating eukaryotic host cells for expression of a gene product of interest, wherein these nucleic acid constructs are used, and to methods for producing a gene product of interest wherein thus generated host cells are applied.Type: GrantFiled: February 8, 2016Date of Patent: October 23, 2018Assignee: CELLAGENICS B.V.Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, John Antonius Verhees
-
Patent number: 10098933Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: GrantFiled: September 20, 2016Date of Patent: October 16, 2018Assignee: AERase, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: 10093930Abstract: Materials and methods for treating cancer (e.g., by reducing metastasis) are provided herein. For example, materials and methods for treating cancer by targeting WSB1 and/or pVHL are provided.Type: GrantFiled: May 6, 2016Date of Patent: October 9, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Zhenkun Lou, JungJin Kim, SeungBaek Lee
-
Patent number: 10077475Abstract: FRET-based analytes detection and related methods and systems are described where a pair of FRET labeled primers and/or oligonucleotides are used that are specific for target sequences located at a distance up to four time the Förster distance of the FRET chromophores presented on the FRET labeled primers and/or oligonucleotides one with respect to the other in one or more polynucleotide analyte; in particular the pair of FRET labeled primers and/or oligonucleotides is combined with a sample and subjected to one or more polynucleotide amplification reactions before measuring FRET signals from at least one FRET chromophore.Type: GrantFiled: February 26, 2015Date of Patent: September 18, 2018Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Emil P. Kartalov, Aditya Rajagopal, Axel Scherer, Mark D. Goldberg
-
Patent number: 10078090Abstract: The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of Src homology 3 domain binding protein 5 (SH3BP5 or SAB) or the RNA encoding SAB protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of SAB protein or the RNA encoding SAB protein relative to a control sample. The methods of the current invention can be practiced to diagnose and treat a systemic degenerative disease, a neurodegenerative disease, obesity, diabetes, a cancer, or an aging related disease. The invention also provides a kit for diagnosing a disease or diagnosing an increased likelihood of developing the disease in a subject.Type: GrantFiled: December 1, 2017Date of Patent: September 18, 2018Assignee: The Florida International University Board of TrusteesInventor: Jeremy W. Chambers
-
Patent number: 10072290Abstract: The present invention provides methods of amplifying a fragmented target nucleic acid containing short target nucleic acid fragments utilizing an assembler sequence to convert these short fragments into longer sequences enabling their identification and interrogation. This is particularly important when attempting to identify small genetic variations, such as SNVs, present in highly fragmented nucleic acid samples. Amplification is accomplished by hybridizing the short target nucleic acid sequences to the assembler sequence, where these short sequences serve as primers for extension. Since the fragmented target nucleic acids that contain SNVs are utilized as primers on the assembler sequence they are preserved during amplification and can be detected.Type: GrantFiled: March 15, 2014Date of Patent: September 11, 2018Assignee: AEGEA BIOTECHNOLOGIES, INC.Inventors: Lyle J. Arnold, Norman C. Nelson
-
Patent number: 10072285Abstract: Methods of detecting and amplifying short RNAs are provided.Type: GrantFiled: August 17, 2015Date of Patent: September 11, 2018Assignee: Bio-Rad Laboratories, Inc.Inventors: Man Cheng, Xiao-Song Gong, Yan Wang, Adam M. McCoy